For the year ending 2025-12-31, TRVI had -$15,183K decrease in cash & cash equivalents over the period. -$42,101K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Chronic cough in ipf clinical trial expense | 7,992 |
| Refractory chronic cough clinical trial expense | 1,457 |
| Other clinical trials and studies | 6,219 |
| Clinical trial material | 1,827 |
| Other clinical development expenses | 5,942 |
| Employee compensation (excluding stock compensation expense) | 11,820 |
| Stock compensation expense | 5,185 |
| Other segment items | 8,853 |
| Interest income, net | 6,536 |
| Net loss | -42,759 |
| Stock-based compensation | 5,185 |
| Operating lease right-of-use assets | 437 |
| Depreciation and amortization | 144 |
| Accretion of available-for-sale marketable securities, net | 1,638 |
| Write off of deferred offering costs | 26 |
| Loss on disposal of property, equipment and leasehold improvements | -7 |
| Prepaid expenses and other current assets | 1,478 |
| Accrued expenses and other liabilities | -1,415 |
| Accounts payable | -598 |
| Net cash used in operating activities | -42,089 |
| Proceeds from maturities of available-for-sale marketable securities | 76,567 |
| Purchases of available-for-sale marketable securities | 170,662 |
| Purchases of property, equipment and leasehold improvements | 12 |
| Net cash used in investing activities | -94,107 |
| Proceeds from offering, net of commissions | 108,154 |
| Proceeds from exercises of warrants | 10,757 |
| Proceeds from exercises of stock options | 2,079 |
| Proceeds from disgorgement of beneficial owner's short-swing profits | 725 |
| Proceeds from employee stock purchase plan | 118 |
| Payments of offering costs | 809 |
| Payments of finance lease | 11 |
| Net cash provided by financing activities | 121,013 |
| Net (decrease) increase in cash and cash equivalents | -15,183 |
| Cash and cash equivalents at beginning of period | 34,097 |
| Cash and cash equivalents at end of period | 18,914 |
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)